Last reviewed · How we verify

Convalescent Plasma from COVID-19 donors

Fundacion Arturo Lopez Perez · Phase 2 active Biologic

Convalescent Plasma from COVID-19 donors is a Biologic drug developed by Fundacion Arturo Lopez Perez. It is currently in Phase 2 development.

At a glance

Generic nameConvalescent Plasma from COVID-19 donors
SponsorFundacion Arturo Lopez Perez
ModalityBiologic
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Convalescent Plasma from COVID-19 donors

What is Convalescent Plasma from COVID-19 donors?

Convalescent Plasma from COVID-19 donors is a Biologic drug developed by Fundacion Arturo Lopez Perez.

Who makes Convalescent Plasma from COVID-19 donors?

Convalescent Plasma from COVID-19 donors is developed by Fundacion Arturo Lopez Perez (see full Fundacion Arturo Lopez Perez pipeline at /company/fundacion-arturo-lopez-perez).

What development phase is Convalescent Plasma from COVID-19 donors in?

Convalescent Plasma from COVID-19 donors is in Phase 2.

Related